tradingkey.logo

Prophase Labs Inc

PRPH
View Detailed Chart
0.298USD
+0.006+2.02%
Market hours ETQuotes delayed by 15 min
12.37MMarket Cap
LossP/E TTM

Prophase Labs Inc

0.298
+0.006+2.02%
Intraday
1m
30m
1h
D
W
M
D

Today

+2.02%

5 Days

-22.78%

1 Month

-46.80%

6 Months

-9.98%

Year to Date

-60.68%

1 Year

-86.41%

View Detailed Chart

TradingKey Stock Score of Prophase Labs Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Prophase Labs Inc's Score

Industry at a Glance

Industry Ranking
61 / 78
Overall Ranking
457 / 4616
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
16.000
Target Price
+5111.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Prophase Labs Inc Highlights

StrengthsRisks
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.77M.
Overvalued
The company’s latest PE is -0.15, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 2.91M shares, decreasing 47.55% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 137.92K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 4.02.

Prophase Labs Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Prophase Labs Inc Info

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Ticker SymbolPRPH
CompanyProphase Labs Inc
CEOMr. Ted William Karkus
Websitehttps://www.prophaselabs.com/
KeyAI